Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Hits & Misses
    • Artificial Intelligence and Healthcare
    • Doctors & Hospitals
      • COVID-19 and Public Health
    • Policy & Legislation
      • Affordable Care Act
    • Health Economics & Costs
      • Cost of Healthcare
      • Drug Prices & Regulations
      • Health Reform
    • Health Insurance
      • Public Insurance
      • Medicare
    • Telemedicine
      • Medical Tourism
  • Goodman Institute
  • Contact
  • Search
The Goodman Institute Health Blog

Category: Drug Prices & Regulations

Nearly Half of Americans Know Someone Who Died of an Overdose

Posted on February 23, 2024 by Devon Herrick

More than 100,000 Americans die every year from a drug overdose in the United States. In the 12-month period ended in September 2023, 111,380 Americans had died. As recently as 2015  the number of Americans overdosing  was less than half of recent figures, although that’s no small number either. Overdose deaths had risen to about 70,000 just prior to the covid pandemic. Covid appears to be a catalyst that spurred more drug use, resulting in the number of deaths skyrocketing.

+

Friday Links

Posted on February 23, 2024February 22, 2024 by John C. Goodman
  • Coming to the market soon: noninvasive, AI-powered brain decoders that can translate into text the unspoken thoughts swirling through our minds.
  • Another argument that FDA approval for new drugs should depend on safety alone, not efficacy.
  • The US Vaccine Injury Compensation Program has a 10-year backlog of claims.
  • “…the student loan program, as currently written, is looking to be one of the most costly, inefficient and unwise government programs of the 21st century.”
  • More than half of all rural hospitals no longer deliver babies.
+

The Cost of Price Controls on Drugs

Posted on February 21, 2024 by John C. Goodman

We conservatively find that the IRA’s policy to set prices at 9 years after market entry for select small molecule drugs will reduce their expected revenues in the U.S. market by 8.0%, which implies a reduction in R&D investment of almost 12.3%, or $232.1 billion over 20 years. Over the same time frame, we conclude that there will be 188 fewer small molecule treatments, including 79 fewer new small molecule drugs and 109 fewer post-approval indications for these drugs. We find that this forgone innovation is expected to lead to 116.0 million life years lost due to the missed opportunities to improve health.

Source:  Tomas J. Philipson, Yier Ling and Ruiquan Chang, “The Impact of Price Setting at 9 Years on Small Molecule Innovation Under the Inflation Reduction Act.”

+

Wednesday Links

Posted on February 21, 2024February 20, 2024 by John C. Goodman
  • Study:  Too much niacin may increase the risk of cardiovascular disease.  It helps me combat vertigo.
  • A person younger than 18 shot and killed another child somewhere in the United States once a day, every day — on average last year. (NYT)
  • Study: Teens turn to drugs because of stress.
  • Are cancer patients being overdosed with cancer  drugs?
  • Among millions immunized, largest Covid vaccine study yet finds links to health conditions.
+
  • Previous
  • 1
  • …
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • …
  • 237
  • Next

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 42 other subscribers

Popular Topics

©2026 The Goodman Institute Health Blog | Website by Lexicom